Q4 Earnings Forecast for argenx Issued By William Blair

argenx SE (NASDAQ:ARGX) – William Blair issued their Q4 2026 earnings estimates for shares of argenx in a report issued on Monday, March 17th. William Blair analyst M. Minter anticipates that the company will earn $7.29 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share.

Other research analysts also recently issued reports about the stock. Evercore ISI upped their target price on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Citigroup reiterated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Robert W. Baird increased their price target on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research report on Tuesday, March 4th. Truist Financial reiterated a “buy” rating and issued a $700.00 price target (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company increased their target price on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Trading Up 1.5 %

argenx stock opened at $614.19 on Tuesday. argenx has a 1 year low of $349.86 and a 1 year high of $678.21. The company has a market cap of $37.32 billion, a PE ratio of -697.94 and a beta of 0.59. The company’s 50-day moving average is $637.58 and its two-hundred day moving average is $597.56.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million.

Institutional Investors Weigh In On argenx

Several hedge funds have recently added to or reduced their stakes in the business. Lansforsakringar Fondforvaltning AB publ acquired a new stake in argenx during the 4th quarter valued at $267,000. Brucke Financial Inc. acquired a new position in argenx in the fourth quarter valued at about $412,000. Mackenzie Financial Corp raised its stake in argenx by 81.4% in the fourth quarter. Mackenzie Financial Corp now owns 4,449 shares of the company’s stock valued at $2,736,000 after purchasing an additional 1,996 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in argenx in the fourth quarter valued at about $416,000. Finally, Vise Technologies Inc. raised its stake in argenx by 6.8% in the fourth quarter. Vise Technologies Inc. now owns 799 shares of the company’s stock valued at $491,000 after purchasing an additional 51 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.